Price To Earnings Ratio 49.88 | Sector PE 69.47 |
PB Ratio 9.90 | Sector PB 9.32 |
EPS 35.61 | Dividend Yield 0.74 |
Today's Volume 153.436 K | 5 Day Avg. Volume 186.174 K |
PEG Ratio -1.52 | Market Cap. ₹ 26,970.00 Cr. |
Time | JBCHEPHARM | VS | Industry |
---|---|---|---|
1 Day | 0.03% | 0.19% | |
1 Week | 2.64% | 3.31% | |
1 Month | -7.71% | 0.92% | |
6 Months | -9.81% | 22.41% | |
1 Year | 21.7% | 48.28% |
Period (Days) | SMA | Indication |
---|---|---|
10 | 1753.05 | Bullish |
20 | 1763.39 | Bullish |
30 | 1808.47 | Bearish |
50 | 1822.48 | Bearish |
100 | 1860.58 | Bearish |
200 | 1795.37 | Bearish |
Annual | FY 2024 | FY 2023 | FY 2022 | ||||
---|---|---|---|---|---|---|---|
Operating Activities | 800.61 | 625.61 | 170.13 | ||||
Investing Activities | -403.83 | -961.79 | 2.32 | ||||
Financing Activities | -385.49 | 356.54 | -138.39 | ||||
Net Cash Flow | 11.30 | 20.36 | 34.07 |
All Figures in ₹ Cr., unless mentioned otherwise
Name | 1D (%) | 1W (%) | 1M (%) | 6M (%) | 1Y (%) |
---|---|---|---|---|---|
J.B. Chemicals & Pharmaceuticals | 0.03 | 2.64 | -7.71 | -9.81 | 21.7 |
Advanced Enzyme Tech | -0.36 | -4.67 | -22.41 | 0.59 | 14.32 |
Alembic | 1.66 | 6.55 | 4.98 | 2.76 | 2.76 |
Aster DM Healthcare | 0.53 | 1.16 | 8.71 | 30.54 | 14.36 |
Divi's Laboratories | 1.54 | 4.35 | 6.03 | 38.79 | 67.77 |
J. B. Chemicals & Pharmaceuticals Limited is an Indian pharmaceutical company. The company's field of activity is the production and distribution of various medicines, herbal preparations and active ingredients (API). It is engaged in the production of product development services. The company offers a variety of products and formulations in various therapeutic categories, including gastroenterology, hypertension, dermatology, nephrology, respiratory infections, virology, diabetes, wound care, anti-infectives, pharmacovigilance and nicotine replacement therapy (NRT). Its product range includes lozenges, which include centre-filled, soft-centre lozenges, centre-filled, powder lozenges, herbal tablets and medicinal preparations. Products in this API include diclofenac sodium, diclofenac diethylamine, diclofenac acid, diclofenac potassium, nifedipine, atenolol, cilnidipine, and ciprofloxacin HCl. The company also owns the Razel (Rousvastatin) franchise in India and Nepal.